| Literature DB >> 27631002 |
Abdul-Rehman Phull1, Seong-Hui Eo1, Qamar Abbas1, Madiha Ahmed2, Song Ja Kim1.
Abstract
Chondrocytes are the exclusive cells residing in cartilage and maintain the functionality of cartilage tissue. Series of biocomponents such as different growth factors, cytokines, and transcriptional factors regulate the mesenchymal stem cells (MSCs) differentiation to chondrocytes. The number of chondrocytes and dedifferentiation are the key limitations in subsequent clinical application of the chondrocytes. Different culture methods are being developed to overcome such issues. Using tissue engineering and cell based approaches, chondrocytes offer prominent therapeutic option specifically in orthopedics for cartilage repair and to treat ailments such as tracheal defects, facial reconstruction, and urinary incontinence. Matrix-assisted autologous chondrocyte transplantation/implantation is an improved version of traditional autologous chondrocyte transplantation (ACT) method. An increasing number of studies show the clinical significance of this technique for the chondral lesions treatment. Literature survey was carried out to address clinical and functional findings by using various ACT procedures. The current study was conducted to study the pharmacological significance and biomedical application of chondrocytes. Furthermore, it is inferred from the present study that long term follow-up studies are required to evaluate the potential of these methods and specific positive outcomes.Entities:
Mesh:
Year: 2016 PMID: 27631002 PMCID: PMC5007317 DOI: 10.1155/2016/1879837
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Mesenchymal stem cells (MSCs) differentiations towards chondrocytes and other cell types. Differentiation and growth factors profile are schematically represented in sequence. Characteristic extracellular matrix (ECM) proteins at different stages are presented. Col, collagen; COMP, cartilage oligomeric protein; CD-RAP, cartilage-derived retinoic acid-sensitive protein; AP, alkaline phosphatase; MMP, matrix metalloprotease; BMPs, bone morphogenetic proteins; FGF, fibroblast growth factor; Wnt, Wingless Factors; TGF, transforming growth factor; IGF, insulin-like growth factor; VEGF, vascular endothelial growth factor.
Advantage and disadvantages associated with the cells sources used in tissue engineering for cartilage repair.
| Cell type | Advantage | Disadvantage/limitations |
|---|---|---|
| (i) Chondrocytes | (i) Promising cell source for cartilage repair | (i) Donor-site morbidity caused by cartilage harvest |
|
| ||
| (ii) Adult mesenchymal stem cells (MSCs) | (i) Easily obtained from tissues such as adipose tissue, bone marrow, and synovial membrane | (i) Potential risks of induction or stimulation of tumorigenesis, colonization of nontarget tissues, transmission of infection, use of human (allogeneic) or animal serum-derived agents during cell expansion |
|
| ||
| (iii) Induced pluripotent stem cells (iPSCs) | (i) iPSCs have showed promising result in cartilage repair | (i) Chondrogenic efficacy of iPSCs |
|
| ||
| (iv) Embryonic stem cells (ESCs) | (i) Coculture with mature chondrocytes stimulates ESC chondrogenesis | (i) Teratoma formation |
Figure 2Various major cell sources used in tissue engineering studies.
Differences of autologous transplantation/implantation generations.
| First generation | Second generation | Third generation | |
|---|---|---|---|
| Description | Autologous chondrocyte suspension with periosteum | Autologous chondrocyte suspension with collagen membrane | Autologous chondrocyte suspension in biomaterials |
|
| |||
| Cells source/delivery | Carticel, periosteum patch | Chondro-Gide | MACI®, CaReS®, Tissucol®, NeoCart |
Adopted from Samsudin and Kamarul, 2015 [101].
Figure 3Application potential of the chondrocyte in tissue engineering based application.